Project Grant R01HL172975
Award Date
7/1/25
Completion Date
3/31/30
Dollars Obligated
$684K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $277,610 to Duke University to support research on the role of TP53 regulation in alveolar epithelial transitional cell state and its contribution to pulmonary fibrosis. The research aims to uncover the molecular mechanisms that drive alveolar epithelial cell transitions and their potential impact on the pathogenesis of...
This $651,019 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to elucidate the mediators and pathways that contribute to dysfunctional epithelial repair in pulmonary fibrosis. The grant, awarded to the Regents of the University of Michigan, aims to: 1) identify factors driving dysfunctional epithelial states in persistent lung fibrosis, 2) determine the impact of...
This $774,585 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) supports research to investigate the role of inflammatory fibroblasts in pulmonary fibrosis. The key objectives are to: Determine the mechanisms driving the emergence of inflammatory fibroblasts from normal alveolar fibroblasts and how these cells modulate inflammatory responses and fibrosis in different lung injury models....
This federal Project Grant award, in the amount of $1,546,880, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports research to investigate the regulation of the myofibroblast program in idiopathic pulmonary fibrosis. The research aims to determine the "regulatory architecture" of open chromatin in myofibroblasts, explore how expression levels of E-box transcription factors regulate...
This federal Project Grant award, valued at $616,000.00 and funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research at Northwestern University to investigate the role of mitochondrial metabolism in alveolar epithelial cell differentiation and the development of lung fibrosis. The funded project aims to determine whether an increased mitochondrial NADH/NAD+ ratio and activation of the integrated stress...
This $787,266 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Program (CFDA 93.837) supports research to investigate the role of basal-like cells and WNT7A signaling in idiopathic pulmonary fibrosis (IPF). The goal is to test the hypothesis that dysregulated signaling pathways in pathologically accumulated basal-like cells in IPF lungs promote fibrosis by activating WNT signaling, leading to impaired renewal of type 2...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $5,715,866 to develop novel, transformative therapies that reduce the burden of morbidity and mortality from progressive pulmonary fibrosis (PF). The 5-year project, awarded on September 17, 2024, aims to re-shape understanding of the natural history of PF by investigating transcriptomic, genetic, epigenetic, metabolic, and environmental factors that contribute to...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $695,403 to the University of Arizona to conduct research aimed at therapeutically targeting pulmonary endothelial cells to inhibit the progression of pulmonary fibrosis. The key objectives are to: 1) Determine whether restoring microvascular integrity via nanoparticle gene therapy can inhibit lung fibrogenesis, and 2) Define whether...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $170,543 to Virginia Commonwealth University (VCU) for a 2-year period from September 1, 2024 to August 31, 2026. The funding supports research to characterize the mechanism by which the mechanoreceptor PIEZO2 drives metabolic adaptations in response to increased lung matrix stiffness, and how these metabolic changes contribute to...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $242,310 Project Grant to The Regents of the University of California, San Francisco (UCSF) on July 1, 2024 under the Cardiovascular Diseases Research program (CFDA 93.837). The grant, titled "ADAPTING CELL-BASED THERAPIES FOR THE TREATMENT OF PULMONARY FIBROSIS", will support research aimed at developing innovative cell-based therapies for the treatment of pulmonary fibrosis, a chronic and debilitating lung disease. UCSF,...